Skip to main content

Something Superior?


A new study published in Lancet Oncology says that the breast cancer drug letrozole reduces breast cancer recurrence rates and improves survival rates better than tamoxifen, reports The New York Times' Anahad O'Connor. The study involved 8,010 postmenopausal ER+ breast cancer patients who were randomly assigned to receive either letrozole — sold by Novartis under the brand name Femara — or tamoxifen for five years, or both drugs taken in sequence, letrozole for two years followed by tamoxifen for three or vice versa. After a follow-up of about eight years, the researchers found that women given letrozole after surgery had a 20 percent lower risk of breast cancer recurrence and were 21 percent less likely to die from cancer, compared with tamoxifen, O'Connor says. The combination treatment did not significantly lower likelihood of recurrence or death, she adds.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.